Ad Header



The Pulse of the Pharmaceutical Industry

  • Filter By Category

  • Filter By Author

Page 3 of 812345...Last »

Novartis’ Zykadia gets positive results

Novartis’ Zykadia drug performed well against a rare form of lung cancer, citing a study the Swiss company hopes will help it win expanded regulatory approval.

Read More »

Saga Continues for Sarepta as FDA Head Calls for Retraction of ‘Misleading’ 2013 Study

The months-long drama involving Sarepta Therapeutics’ eteplilrsen for Duchenne Muscular Dystrophy (DMD) and the U.S. Food and Drug Administration is not over, despite the drug’s accelerated approval.

Read More »

H. Lundbeck’s Phase III Data Crushes Hope for Alzheimer’s Once Again

Danish company H. Lundbeck A/S announced its experimental Alzheimer’s treatment idalopirdine failed in a late-stage trial.

Read More »

U.S. states sue opioid-maker Indivior, alleging anticompetitive practices

Thirty-five U.S. states and the District of Columbia filed a lawsuit against opioid drug maker Indivior alleging it tried to keep generic versions of a drug off the market.

Read More »

Hard to swallow: emerging markets get tougher for drugmakers

Emerging markets have lost their luster for Big Pharma making drug firms ever more dependent on the United States for growth just as American anger over high medicine prices is building.

Read More »

UnitedHealth trims drug coverage

UnitedHealth Group, the largest U.S. health insurer, will stop covering several brand-name drugs as of 2017, including Sanofi’s long-acting insulin Lantus.

Read More »

UK okays Alexion drug costing up to $2 million but wants price cut

A new drug to treat a rare inherited bone disorder that was developed by Alexion Pharmaceuticals and could cost up to 1.5 million pounds ($2 million) a year per patient has been cleared for limited use by Britain’s health cost watchdog.

Read More »

Chan, Zuckerberg Pledge $3 Billion for Diseases

The Chan Zuckerberg Initiative has pledged $3 billion towards basic science research over the next 10 years for all diseases to be cured, prevented or managed.

Read More »

McCann Health Launches ‘Consulting at McCann Health’

McCann Health, the most awarded global professional and consumer health communications network, is creating a new global consultancy called ‘Consulting at McCann Health.’

Read More »

U.S. lawmakers blast Mylan CEO over ‘sickening’ EpiPen price hikes

U.S. lawmakers blasted Mylan NV Chief Executive Heather Bresch for sharply increasing prices for the EpiPen emergency allergy treatment at a congressional hearing in which Republicans and Democrats questioned the reasons behind rising U.S. drug costs.

Read More »

Gilead Terminates Ulcerative Colitis Drug Study

Following a disappointing review of interim data from a clinical study of GS-5745, an investigational anti-MMP9 antibody, Gilead said the company will halt the trial.

Read More »

Disease-related malnutrition costs U.S. $15.5 billion annually: study

The United States could save at least $15.5 billion in annual healthcare spending if malnutrition caused by chronic diseases is better addressed, according to a study.

Read More »

House committee reviewing FDA criminal office

A U.S. congressional committee has launched an examination of the FDA’s criminal office, raising questions about the unit’s management and handling of cases.

Read More »

Zika no threat to plasma-derived drugs, says EU regulator

Patients who take medicines derived from blood plasma or urine are not at increased risk of catching Zika, even if the body fluids come from countries where the virus is prevalent, Europe’s drugs regulator said.

Read More »

AstraZeneca pulls EU cancer drug application

AstraZeneca has pulled an application seeking European approval to sell its experimental cancer drug cediranib in combination with chemotherapy to treat ovarian cancer.

Read More »

Genentech Gambles $310 Million+ on German Biotech BioNTech’s mRNA Cancer Vaccine Tech

Genentech and Germany’s BioNTech AG are teaming up to develop and sell messenger RNA (mRNA)-based cancer vaccines.

Read More »

Senate Republicans seek probe of Mylan EpiPen oversight

Mylan NV faced new scrutiny over price hikes for its anti-allergy EpiPen, with U.S. lawmakers calling for a probe of oversight of the company’s rebates to government healthcare plans, while West Virginia said it was investigating whether Mylan defrauded its Medicaid department.

Read More »

Akarna Therapeutics acquired by Allergan

Akarna Therapeutics Ltd. announced that it has been acquired by Allergan plc. Allergan obtains rights to AKN-083, Akarna’s lead product candidate for the potential treatment of non-alcoholic steatohepatitis (NASH) and other liver diseases.

Read More »

James Mackie Promoted To Partner At The Greater Than One Group

NEW YORK, NY (September 20, 2016) – The Greater Than One (GTO) Group, a leading communications company, announced the promotion of James Mackie to Partner, adding depth to a team of executives designed to improve the customer experience and performance through insight-driven strategic planning and measurement. Mr. Mackie is the GTO Group’s latest high-profile hire […]

Read More »

China Vitamin C price-fixing verdict voided by U.S. appeals court

A U.S. appeals court threw out a $147.8 million price-fixing verdict against two Chinese companies that were accused of conspiring to raise prices and lower supply of vitamin C sold to U.S. purchasers.

Read More »

Page 3 of 812345...Last »

Ad Right Top


Extensive pharmaceutical business and marketing intelligence. For back issues, please contact

August 2018 Focus: Top 200 Meds, Year After Launch, VR/AR and more!


Ad Right Bottom